000283113 001__ 283113
000283113 005__ 20260103103703.0
000283113 0247_ $$2doi$$a10.1002/alz70861_108005
000283113 0247_ $$2ISSN$$a1552-5260
000283113 0247_ $$2ISSN$$a1552-5279
000283113 037__ $$aDZNE-2026-00009
000283113 082__ $$a610
000283113 1001_ $$aRuiz, Agustin$$b0
000283113 1112_ $$aAlzheimer’s Association International Conference$$cToronto$$d2025-07-27 - 2025-07-31$$gAAIC 25$$wCanada
000283113 245__ $$aLong‐Read Sequencing Reveals Ancestral intragenic APOE Haplotypes with Distinct Roles in Alzheimer’s Disease
000283113 260__ $$c2025
000283113 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1767354741_32513
000283113 3367_ $$033$$2EndNote$$aConference Paper
000283113 3367_ $$2BibTeX$$aINPROCEEDINGS
000283113 3367_ $$2DRIVER$$aconferenceObject
000283113 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$mjournal
000283113 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000283113 3367_ $$2ORCID$$aOTHER
000283113 520__ $$aBackground:The apolipoprotein E (APOE) ε4 allele remains the strongest genetic risk factor for late-onset Alzheimer’s disease (AD), yet the marked variability in its pathogenicity suggests underlying genetic complexity. Historically, efforts to resolve the intragenic architecture of APOE have been hampered by the limitations of conventional genotyping and short-read sequencing, as well as the presence of homoplasy in common intragenic markers—misleading similarities arising from convergent variants.Objective:We leveraged Oxford Nanopore Technology (ONT) to phase intragenic APOE variants, resolve homoplasy, and examine the impact of phased haplotypes on cerebrospinal fluid (CSF) APOE protein levels and AD progression.Methods:Using long-read sequencing in a Spanish memory clinic cohort (n = 1,267), we reconstructed full-length 4 kb APOE haplotypes, identifying 59 unique configurations grouped into five major haplogroups. Common intragenic variants defined ancestral ε4 (4A, 4B) and ε3 (3A, 3B) haplogroups. These were analyzed for associations with CSF APOE levels (Olink platform) and progression from mild cognitive impairment (MCI) to dementia using adjusted Cox regression models.Results:ONT sequencing successfully resolved homoplasy between the APOE promoter region—particularly at rs405509—and the canonical protein isoforms, uncovering common but functionally distinct ε3A/B and ε4A/B intragenic sub-haplotypes with independent biological effects. Carriers of the ε4A haplotype exhibited significantly lower CSF APOE protein levels (p = 0.004), whereas the ε3B haplotype was associated with elevated CSF APOE protein levels (p = 0.025). Notably, both haplotypes were linked to a slower progression from MCI to AD, independent of APOE genotype, age, sex and core CSF biomarkers.Conclusion:This study redefines the human APOE ε3 and ε4 alleles as genetically heterogeneous entities. Using ONT long-read sequencing, we achieved high-resolution mapping of intragenic haplotypic structure and regulatory variation previously obscured by conventional approaches. This enabled the identification of ancestral haplotypes with distinct functional profiles and potential relevance to Alzheimer’s disease pathogenesis. These findings highlight the importance of incorporating haplotype-level resolution into Alzheimer’s risk assessment, therapeutic targeting, and precision medicine strategies.
000283113 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283113 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000283113 7001_ $$aGarcía-González, Pablo$$b1
000283113 7001_ $$aPuerta, Raquel$$b2
000283113 7001_ $$aCano, Amanda$$b3
000283113 7001_ $$aOlivé, Clàudia$$b4
000283113 7001_ $$aMarquié, Marta$$b5
000283113 7001_ $$aValero, Sergi$$b6
000283113 7001_ $$aRosende-Roca, Maitee$$b7
000283113 7001_ $$aSanz, Pilar$$b8
000283113 7001_ $$aAlegret, Montserrat$$b9
000283113 7001_ $$0P:(DE-2719)2810593$$aBrosseron, Frederic$$b10$$udzne
000283113 7001_ $$aMartino-Adami, Pamela$$b11
000283113 7001_ $$ade Rojas, Itziar$$b12
000283113 7001_ $$0P:(DE-2719)2000008$$aHeneka, Michael T.$$b13
000283113 7001_ $$0P:(DE-2719)2812825$$aRamirez, Alfredo$$b14$$udzne
000283113 7001_ $$aNavarro, Arcadi$$b15
000283113 7001_ $$aSáez, María Eugenia$$b16
000283113 7001_ $$aTárraga, Lluís$$b17
000283113 7001_ $$aCavazos, José E.$$b18
000283113 7001_ $$aBoada, Mercè$$b19
000283113 7001_ $$aFernández, Victoria$$b20
000283113 7001_ $$aSocorro, Alfredo Cabrera$$b21
000283113 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz70861_108005$$gVol. 21, no. S7, p. e108005$$nS7$$pe108005$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000283113 8564_ $$uhttps://pub.dzne.de/record/283113/files/DZNE-2026-00009.pdf$$yOpenAccess
000283113 8564_ $$uhttps://pub.dzne.de/record/283113/files/DZNE-2026-00009.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000283113 909CO $$ooai:pub.dzne.de:283113$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000283113 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810593$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000283113 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2812825$$aExternal Institute$$b14$$kExtern
000283113 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283113 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000283113 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000283113 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283113 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000283113 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000283113 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283113 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000283113 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000283113 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000283113 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000283113 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000283113 9201_ $$0I:(DE-2719)1011303$$kAG Heneka$$lNeuroinflammation, Biomarker$$x0
000283113 980__ $$aabstract
000283113 980__ $$aVDB
000283113 980__ $$aUNRESTRICTED
000283113 980__ $$ajournal
000283113 980__ $$aI:(DE-2719)1011303
000283113 9801_ $$aFullTexts